## PLACEBO (FORMULE 515 AP-HP): A FRENCH OBSERVATIONAL SURVEY

DI 011

### Léa LAMIRAND, Jean-Meidi ALILI, Marie-Pierre BERLEUR, Marie-Caroline HUSSON

Regulatory, Pharmaceutical and Medical Department, Pharmaceutical Establishment of Paris Hospitals Group, AP-HP, Paris, France jean-meidi.alili@aphp.fr; marie-caroline.husson@aphp.fr

### **Background and Objective**

Pharmaceutical Establishment of Paris Hospitals Group (PE AP-HP) provides

French health care professionals with placebo hospital preparation

'Formule 515 AP-HP tablet' (F515).


Observational survey conducted in French Hospitals

→ To evaluate the therapeutic interest of F515

# Setting and Method Main outcome measures Survey: July to December 2018 in 79 French hospitals users of F515 during the past 4 years Clinicians Mean duration of the treatment?

### **Results - Discussion**

> Seventy-nine hospitals were contacted, 39/79 (49%) answered the questionnaire.



Some non-respondents to this survey may have been embarrassed due to the **ethical issues** raised by the use of this particular drug.

### Conclusion

- > The **therapeutic interest** of F515 was **confirmed** by most professionals in this survey.
- > It is appropriate that PE AP-HP continue to manufacture this drug for French hospitals.





